Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock

Key Points

• Insider Solomon Moshkevich sold 3,000 shares of Natera on April 1 at an average price of $202.30 for about $606,900 under a pre-arranged Rule 10b5-1 plan, leaving him with 147,882 shares valued at roughly $29.9M (a 1.99% reduction).
• Moshkevich has repeatedly sold large blocks of NTRA stock since January — including a 23,205-share sale on Jan. 20 — indicating an ongoing pattern of insider disposals.
• Natera recently beat quarterly EPS and revenue estimates, trades around $208 with a market cap near $29.5B, and carries a consensus analyst rating of Moderate Buy with a $253.47 target price.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $202.30, for a total value of $606,900.00. Following the transaction, the insider directly owned 147,882 shares in the company, valued at approximately $29,916,528.60. This represents a 1.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.

Natera Price Performance

Shares of NTRA remained flat at $207.98 on Friday. 1,279,670 shares of the company were exchanged, compared to its average volume of 1,236,684. The stock has a market cap of $29.48 billion, a PE ratio of -135.93 and a beta of 1.68. The stock's 50 day simple moving average is $207.26 and its 200 day simple moving average is $209.16. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the prior year, the business posted ($0.41) earnings per share. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

A number of large investors have recently made changes to their positions in NTRA. Reflection Asset Management bought a new position in Natera during the fourth quarter worth about $29,000. Palladiem LLC bought a new stake in shares of Natera in the fourth quarter worth about $31,000. Horizon Investments LLC acquired a new stake in shares of Natera during the third quarter worth about $32,000. Bank of Jackson Hole Trust lifted its holdings in shares of Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its holdings in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company's stock valued at $39,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on NTRA shares. Wall Street Zen raised Natera from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. Citigroup started coverage on Natera in a research note on Wednesday, January 7th. They issued a "buy" rating and a $300.00 target price on the stock. Wells Fargo & Company raised their target price on Natera from $205.00 to $215.00 and gave the stock an "equal weight" rating in a report on Friday, February 27th. Morgan Stanley decreased their target price on Natera from $265.00 to $250.00 and set an "overweight" rating for the company in a research report on Tuesday, March 3rd. Finally, TD Cowen reiterated a "buy" rating on shares of Natera in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.